These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30363496)

  • 21. Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy.
    Feibus AH; Sartor O; Moparty K; Chagin K; Kattan MW; Ledet E; Levy J; Lee B; Thomas R; Silberstein JL
    J Urol; 2016 Oct; 196(4):1053-60. PubMed ID: 27140073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics.
    Mytsyk Y; Nakonechnyi Y; Dosenko V; Kowal P; Pietrus M; Gazdikova K; Labudova M; Caprnda M; Prosecky R; Dragasek J; Kruzliak P; Dats R
    Clin Biochem; 2023 Jun; 116():120-127. PubMed ID: 37121562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen and other serum and urine markers in prostate cancer.
    Stephan C; Ralla B; Jung K
    Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
    Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA
    Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study.
    Tosoian JJ; Dunn RL; Niknafs YS; Saha A; Vince RA; St Sauver JL; Jacobson DJ; McGree ME; Siddiqui J; Groskopf J; Jacobsen SJ; Tomlins SA; Kunju LP; Morgan TM; Salami SS; Wei JT; Chinnaiyan AM; Sarma AV
    Eur Urol Open Sci; 2021 Jul; 29():30-35. PubMed ID: 34337531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
    Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L
    Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men.
    Hendriks RJ; van der Leest MMG; Israël B; Hannink G; YantiSetiasti A; Cornel EB; Hulsbergen-van de Kaa CA; Klaver OS; Sedelaar JPM; Van Criekinge W; de Jong H; Mulders PFA; Crawford ED; Veltman J; Schalken JA; Barentsz JO; van Oort IM
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1110-1119. PubMed ID: 33941866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    Sanda MG; Feng Z; Howard DH; Tomlins SA; Sokoll LJ; Chan DW; Regan MM; Groskopf J; Chipman J; Patil DH; Salami SS; Scherr DS; Kagan J; Srivastava S; Thompson IM; Siddiqui J; Fan J; Joon AY; Bantis LE; Rubin MA; Chinnayian AM; Wei JT; ; Bidair M; Kibel A; Lin DW; Lotan Y; Partin A; Taneja S
    JAMA Oncol; 2017 Aug; 3(8):1085-1093. PubMed ID: 28520829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Molecular Markers for Prostate Cancer Diagnosis.
    Amiri M; Asadi Samani L; Kashi AH; Khadem N; Ziaee SAM; Mowla SJ
    Urol J; 2024 Feb; 21(1):1-13. PubMed ID: 37818554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
    Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
    Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. External validation of a PCA-3-based nomogram for predicting prostate cancer and high-grade cancer on initial prostate biopsy.
    Greene DJ; Elshafei A; Nyame YA; Kara O; Malkoc E; Gao T; Jones JS
    Prostate; 2016 Aug; 76(11):1019-23. PubMed ID: 27197726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.
    Donovan MJ; Noerholm M; Bentink S; Belzer S; Skog J; O'Neill V; Cochran JS; Brown GA
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):370-5. PubMed ID: 26345389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer.
    Krilaviciute A; Becker N; Lakes J; Radtke JP; Kuczyk M; Peters I; Harke NN; Debus J; Koerber SA; Herkommer K; Gschwend JE; Meissner VH; Benner A; Seibold P; Kristiansen G; Hadaschik B; Arsov C; Schimmöller L; Giesel FL; Antoch G; Makowski M; Wacker F; Schlemmer HP; Kaaks R; Albers P
    Eur Urol Oncol; 2023 Dec; 6(6):566-573. PubMed ID: 37806841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
    Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
    Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in Diagnosis and Prognosis.
    Matuszczak M; Schalken JA; Salagierski M
    Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers for prostate cancer detection and risk stratification.
    Farha MW; Salami SS
    Ther Adv Urol; 2022; 14():17562872221103988. PubMed ID: 35719272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.